|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A01K 67/027 | |
| C07K 14/535 | |||
| C07K 14/715 | |||
| C07K 14/54 | |||
| C07K 14/52 | |||
| C07K 14/505 | |||
| C12N 9/00 | |||
| A61K 49/00 | |||
| G01N 33/50 | |||
| C07K 14/47 |
| (11) | Number of the document | 3482629 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18214077.2 |
| Date of filing the European patent application | 2015-05-18 | |
| (97) | Date of publication of the European application | 2019-05-15 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-25 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201462000460 P | 2014-05-19 | US |
| (72) |
MURPHY, Andrew J., US
STEVENS, Sean, US
FLAVELL, Richard, US
MANZ, Markus, CH
SHAN, Liang, US
|
| (73) |
Yale University,
Two Whitney Avenue, New Haven, CT 06510,
US
Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, US Institute for Research in Biomedicine (IRB), Via Vincenzo Vela 6,, 6501 Bellinzona, CH |
| (54) | GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO |